ASCO 2022 Conference Coverage


 

ASCO 2022: The ImPrint Immune Signature to Identify Patients With High-Risk eBC Who May Benefit From PD-1 Checkpoint Inhibition in I-SPY2

254 views
June 8, 2022
0 Comments
Login to view comments. Click here to Login
Breast